Phase III Randomized Trial of Intravenous Cisplatin Plus a 24- or 96-Hour Infusion of Paclitaxel in Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study
David R. Spriggs(Massachusetts General Hospital), Mark G. Hanly(Gynecologic Oncology Group), John F. Boggess(University of Kentucky), Robert A. Burger(Mersana Therapeutics (United States)), Robert S. Mannel(University of Oklahoma Health Sciences Center), Mark F. Brady(Brown University), Luis Vaccarello(Gynecologic Oncology Group), Daniel L. Clarke‐Pearson(University of North Carolina at Chapel Hill), Roger B. Lee(Gynecologic Oncology Group)
Cited by 57
Related Papers
A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study
|The Lancet Oncology|2017|929
Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study
|Journal of Clinical Oncology|2007|880
The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma
|American Journal of Obstetrics and Gynecology|1994|670
Phase III Study of Cisplatin With or Without Paclitaxel in Stage IVB, Recurrent, or Persistent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study
|Journal of Clinical Oncology|2004|644
American Society of Clinical Oncology Position Statement on Obesity and Cancer
|Journal of Clinical Oncology|2014|524